Tweets like “GSK illegally markets drugs” or “Remarkable story in the Washington Post about Glaxo obfuscation” would seem unlikely to land a writer a job on a pharma co’s executive board, but Cori Bargmann’s AstraZeneca experience proves otherwise.
The Wall Street Journal reports that AstraZeneca has nominated the Howard Hughes Medical Institute Investigator and industry critic for a seat on its board. Bargmann told the Journal, “I don’t consider myself a pharma critic — just inexperienced.”
AstraZeneca wouldn’t tell the WSJ if they knew about her pre-nomination Tweets, but an expert told the paper a skeptic could be an executive asset.
